Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04546737

Acronym

NSpectroCovid

Enrollment

Registered

2020-09-14

Start date

2020-09-02

Completion date

2026-01-21

Last updated

2026-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Damage, Covid19, Neurological Manifestations

Keywords

Covid19, Neurological Manifestations, MRI and NMR spectroscopy, Radiological semiology, Spectral profile, Brain Damage

Brief summary

Viral pandemics, such as HIV and SARS-Cov-V1, have shown that they can lead to acute and / or delayed neurological complications. At the actual context of the pandemic Coronavirus disease 2019 (COVID-19), neurological manifestations seem to be confirmed since in 85% of COVID-19 patients, present neurological symptoms, including anosmia, ageusia, periorbital pain, dizziness, fatigue, even moderate headache, moderate memory and/or behavioral disorders. However, these neurological manifestations are not well studied and their radiological features are not well described. It is therefore important to assess these potential neurological complications in COVID-19 patients. To the investigator knowledge, there is no previous study in the literature describing spectral brain changes in COVID + patients. Thus, the goal of this work is to describe the radiological semiology using MRI and particularly Magnetic Resonance Spectroscopic (MRS) biomarkers in the evaluation of acute and / or delayed brain damage in COVID + patients presenting a neurological manifestations that are initially related to the cranial nerves damage.

Interventions

OTHERMagnetic Resonance Spectroscopy (MRS).

This is a Nuclear Magnetic Resonance (NMR) technique which can detect the NMR signal allowing to measure under curves areas, amplitudes, ratios and concentrations of various metabolites contained in a biological tissue, in addition to water and lipids. This offers the possibility, in addition to the contribution of MRI imaging, to better characterize pathological processes (inflammatory, infectious, etc.) through spectral and metabolic changes that can be quantitatively evaluated. Spectroscopic measurements will be carried out with a mono-voxel spectroscopy using a PRESS \[Point RESolved Spectroscopy\] sequence with a short Echo Time (TE) of 35 ms, an intermediate TE of 144 ms and a long TE of 288 ms.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Major COVID-19 patient (≥18 years old) * COVID-19 patient presenting at least one the neurological manifestations: anosmia, ageusia, periorbital pain, dizziness, fatigue, moderate headache, moderate memory and behavioral disorders. * Patient who have signed an informed consent form for the study

Exclusion criteria

* Patient under guardianship or curators or under judicial protection * Pregnant and breastfeeding women

Design outcomes

Primary

Measure	Time frame	Description
Variation from baseline of MRI radiological semiology in COVID-19 patients	9 months after patient inclusion	The radiological semiology as described by MRI and particularly Magnetic Resonance Spectroscopic (MRS) biomarkers in the COVID-19 patients presenting neurological manifestations related initially to the cranial nerves damage.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 12, 2026